New and emerging targeted systemic therapies: a new era for atopic dermatitis
Purpose: This is a review of emerging targeted, systemic therapies for atopic dermatitis (AD). The information presented aims to provide dermatologists with updated therapeutic options, stimulate academic interest, and spark future research. Material and methods: Extensive search of ClinicalTrials.g...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-05-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2017.1373736 |
| _version_ | 1797683759073460224 |
|---|---|
| author | Dylan E. Lee Ashley K. Clark Khiem A. Tran Vivian Y. Shi |
| author_facet | Dylan E. Lee Ashley K. Clark Khiem A. Tran Vivian Y. Shi |
| author_sort | Dylan E. Lee |
| collection | DOAJ |
| description | Purpose: This is a review of emerging targeted, systemic therapies for atopic dermatitis (AD). The information presented aims to provide dermatologists with updated therapeutic options, stimulate academic interest, and spark future research. Material and methods: Extensive search of ClinicalTrials.gov, the National Eczema Association, and PubMed was performed for clinical trials examining the effect of emerging targeted, systemic therapies in patients with AD. Results were included if they demonstrated efficacy in reversing AD symptoms. Studies that did not demonstrate clinical benefit were excluded. Results: A number of emerging systemic agents targeting specific mediators involved in the pathogenesis of AD were found. These targets include IL-4, IL-13, IgE, B-cells, IL-5, IL-31, JAK-STAT, SYK, IL-6, PDE-4, IL-12, IL-17, IL-23, IL-22, H4R, NKR1, κOR, TSLP, PPAR-γ, and DGLA. Treatment of AD patients with these therapies has, in many cases, led to statistically significant improvements in clinical severity scores and patient-reported outcomes. Conclusions: While multiple agents have demonstrated efficacy, only dupilumab is currently approved for adults with AD. Large-scale, randomized, placebo-controlled, double-blind trials, especially in children, are needed. As we enter the dawn of targeted therapy for AD, a comprehensive clinical trial registry is needed to facilitate data pooling and comparison among international registries. |
| first_indexed | 2024-03-12T00:19:29Z |
| format | Article |
| id | doaj.art-b4ccdebb7dee445996676fe5764404bc |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:19:29Z |
| publishDate | 2018-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-b4ccdebb7dee445996676fe5764404bc2023-09-15T14:08:31ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-05-0129436437410.1080/09546634.2017.13737361373736New and emerging targeted systemic therapies: a new era for atopic dermatitisDylan E. Lee0Ashley K. Clark1Khiem A. Tran2Vivian Y. Shi3Creighton University School of MedicineUniversity of California Davis School of MedicineUniversity of Arizona College of MedicineUniversity of Arizona College of MedicinePurpose: This is a review of emerging targeted, systemic therapies for atopic dermatitis (AD). The information presented aims to provide dermatologists with updated therapeutic options, stimulate academic interest, and spark future research. Material and methods: Extensive search of ClinicalTrials.gov, the National Eczema Association, and PubMed was performed for clinical trials examining the effect of emerging targeted, systemic therapies in patients with AD. Results were included if they demonstrated efficacy in reversing AD symptoms. Studies that did not demonstrate clinical benefit were excluded. Results: A number of emerging systemic agents targeting specific mediators involved in the pathogenesis of AD were found. These targets include IL-4, IL-13, IgE, B-cells, IL-5, IL-31, JAK-STAT, SYK, IL-6, PDE-4, IL-12, IL-17, IL-23, IL-22, H4R, NKR1, κOR, TSLP, PPAR-γ, and DGLA. Treatment of AD patients with these therapies has, in many cases, led to statistically significant improvements in clinical severity scores and patient-reported outcomes. Conclusions: While multiple agents have demonstrated efficacy, only dupilumab is currently approved for adults with AD. Large-scale, randomized, placebo-controlled, double-blind trials, especially in children, are needed. As we enter the dawn of targeted therapy for AD, a comprehensive clinical trial registry is needed to facilitate data pooling and comparison among international registries.http://dx.doi.org/10.1080/09546634.2017.1373736atopic dermatitistreatmentsystemictargeted |
| spellingShingle | Dylan E. Lee Ashley K. Clark Khiem A. Tran Vivian Y. Shi New and emerging targeted systemic therapies: a new era for atopic dermatitis Journal of Dermatological Treatment atopic dermatitis treatment systemic targeted |
| title | New and emerging targeted systemic therapies: a new era for atopic dermatitis |
| title_full | New and emerging targeted systemic therapies: a new era for atopic dermatitis |
| title_fullStr | New and emerging targeted systemic therapies: a new era for atopic dermatitis |
| title_full_unstemmed | New and emerging targeted systemic therapies: a new era for atopic dermatitis |
| title_short | New and emerging targeted systemic therapies: a new era for atopic dermatitis |
| title_sort | new and emerging targeted systemic therapies a new era for atopic dermatitis |
| topic | atopic dermatitis treatment systemic targeted |
| url | http://dx.doi.org/10.1080/09546634.2017.1373736 |
| work_keys_str_mv | AT dylanelee newandemergingtargetedsystemictherapiesaneweraforatopicdermatitis AT ashleykclark newandemergingtargetedsystemictherapiesaneweraforatopicdermatitis AT khiematran newandemergingtargetedsystemictherapiesaneweraforatopicdermatitis AT vivianyshi newandemergingtargetedsystemictherapiesaneweraforatopicdermatitis |